# QUALITY PURIFIES.



# Lewatit<sup>®</sup> MDS TP 260 – Significant Cost Savings Offered by Chelating Resin with Special Small-sized Monodisperse Beads

# New approach

Lewatit<sup>®</sup> MDS TP 260 is a new macroporous, monodisperse AMPA-chelating resin with very small particle diameter (approx. 0.42 mm) used for brine purification. Compared to the standard Lewatit<sup>®</sup> TP 260 and Lewatit<sup>®</sup> MonoPlus TP 260 it provides clear economic benefits by cost savings in energy, maintenance, and brine purification. Due to its higher total capacity, faster kinetics, and improved osmotic and mechanical stability, the following advantages arise:


- Up to 100% higher operating capacity enabling
  - Longer cycle times
  - Significantly decreased chemical costs
  - Lower labor costs
  - Less wastewater
  - Longer resin lifetime
- Lower leakage levels and thereby improved protection of electrolyzer membranes
- Removal of strontium and notably barium is considerably improved

## **Operating conditions and results**

Recommended typical operating conditions for Lewatit<sup>®</sup> MDS TP 260 in brine purification are as follows:

- SV = 20 BV/h
- Bed depth approx. 1 m
- T = 60 to 75°C, pH = 8.5 to 10.5
- Backwash: < 4 m/h (@ T < 20°C)
- Regeneration: 150g/I HCl, 80g/I NaOH
- Operating capacities up to 32 g Ca<sup>2+</sup>/Mg<sup>2+</sup> per liter of resin
- Leakage levels below 5 ppb Ca<sup>2+</sup>/Mg<sup>2+</sup> attainable

**Figure 1:** Microscopic image of Lewatit<sup>®</sup> MDS TP 260 and Lewatit<sup>®</sup> MonoPlus TP 260. Monodispersity and the difference in bead size can be clearly seen.



Lewatit<sup>®</sup> MonoPlus TP 260 (Ø = 0.63 mm) Lewatit<sup>®</sup> MDS TP 260 (Ø = 0.42 mm)



### **Application recommendation**

Due to the smaller beads of Lewatit<sup>®</sup> MDS TP 260 there are a few things to consider before use – especially if it is planned to equip an existing filter with the new type of resin:

- Strainer nozzles with 0.3 mm slits can be used but 0.2 mm is preferable
- Freeboard = 100% BV

Contact

LANXESS Deutschland GmbH

Liquid Purification Technologies


Phone: +49 221 8885-0

E-mail: lewatit@lanxess.com

Kennedyplatz 1, 50569 Cologne, Germany

- Backwash linear velocity needs to be reduced by a factor of 3.5 compared to the standard
- Backwash duration increased by a factor of 2 to 3
- Suspended solids load of filter bed should be strictly limited
- Upflow conditioning with 4 % NaOH to be carried out with LV = 3 m/h; depending on column size downflow conditioning preferred in order to avoid fluidization of resin bed
- In case iron(III) is present in brine feed, use of Lewatit<sup>®</sup> MDSTP208 is recommended

Figure 2: Breakthrough curve of Lewatit<sup>®</sup> MDS TP 260 and Lewatit<sup>®</sup> MonoPlus TP 260 measured under comparable operating conditions. The difference in cycle time and Ca leakage can be clearly seen.



#### Operating conditions at exhaustion cycle shown above:

Ca, feed:	5 ppm
NaCl, feed:	300 g/l
pH:	10
SV:	20 BV/h
T:	60°C
Breakthrough:	20 ppb calcium

#### Operating capacity found in exhaustion cycle above:

Lewatit<sup>®</sup> MonoPlus TP 260: 18.2 g Ca/l Lewatit<sup>®</sup> MDS TP 260: 32.3 g Ca/l

#### We will be happy to support your business. Please contact us for additional information: visit www.lpt.lanxess.com



Health and Safety Information: Appropriate literature has been assembled which provides information concerning the health and safety precautions that must be observed when handling the LANXESS products mentioned in this publication. For materials mentioned which are not LANXESS products, appropriate industrial hygiene and other safety precautions recommended by their manufacturers should be followed. Before working with any of these products, you must read and become familiar with the available information on their hazards, proper use and handling. This cannot be overemphasized. Information is available in several forms, e.g., material safety data sheets, product information and product labels. Consult your LANXESS representative in Germany or contact the Regulatory Affairs and Product Safety Department of LANXESS Deutschland GmbH or – for business in the USA – the LANXESS Corporation Product Safety and Regulatory Affairs Department in Pittsburgh, PA, USA.

Regulatory Compliance Information: Some of the end uses of the products described in this publication must comply with applicable regulations, such as the FDA, BIR, NSF, USDA, and CPSC. If you have any questions on the regulatory status of these products, contact – for business in the USA-, the LANXESS Corporation Regulatory Affairs and Product Safety Department in Pittsburgh, PA, USA or for business outside US the Regulatory Affairs and Product Safety Department of LANXESS Deutschland GmbH in Germany. The manner in which you use and the purpose to which you put and utilize our products, technical assistance and information (whether verbal, written or by way of production evaluations), including any suggested formulations and recommendations are beyond our control. Therefore, it is imperative that you test our products, technical assistance and information to determine to your own satisfaction whether they are suitable for your intended uses and applications. This application-specific analysis must at least include testing to determine suitability from a technical assistance agree in writing, all products are sold strictly pursuant to the terms of our standard conditions of sale. All information and technical assistance is given without warranty or guarantee and is subject to change without notice. It is expressly understood and agreed that you assume and hereby expressly release us from all liability, in tort, contract or otherwise, incurred in connection with the use of our products, technical assistance, and information. Any statement or recommendation not contained herein is unauthorized and shall not bind us. Nothing herein shall be construed as a recommendation to use any product in conflict with patents covering any material or its use. No license is implied or in fact granted under the claims of any patent.

0498-EN | 01/071

All trademarks are trademarks of the LANXESS Group, unless otherwise specified. Status 07/2018